Toronto-based biotech Synakis, which develops biomaterial-based treatments for ocular diseases, has secured $2.6M in pre-seed funding. The capital will support the startup's ongoing work in this specialized field.
The investment was provided by Ontario’s Life Sciences Innovation Fund, backing Synakis's focus on creating new biomaterial-based therapies for various eye conditions.















